Who is a good candidate for Mepolizumab therapy?

Good candidates are adults with severe eosinophilic asthma confirmed by blood eosinophil counts ≥150 cells/µL (or ≥300 cells/µL in some guidelines) despite high-dose inhaled corticosteroids and other controllers. Contraindications include known hypersensitivity to mepolizumab or its excipients, active parasitic infections, or pregnancy unless clearly necessary. Patients with non-eosinophilic asthma or mild-to-moderate disease are not suitable.